Zacks Investment Research
01 Jul 2026, 15:45 UTC · 20w ago
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
Impact · against what's priced in
Collegium Pharmaceutical is seeing strong growth in its ADHD franchise and has expanded its portfolio through the Azstarys acquisition. The upward revision of 2026 product revenue guidance to $865-$895 million provides a concrete catalyst for further price appreciation.
- COLL+0.60
No priced-in read yet
- In context
The company raised its 2026 product revenue guidance to $865-$895 million and reported 36% year-over-year sales growth for Jornay PM, indicating strong commercial execution.
Read from the article alone

Search tags




